Clinical Trials
7 trialsNCT07612007 2026-06-01
HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization
Mayo Clinic
Phase 2 Not yet recruiting
NCT05349331 2026-01-15
WATCH
Sun Yat-sen University
Phase 2 Completed
NCT03844750 2025-12-31
Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases
University of California, San Francisco
Phase 2 Terminated
NCT06420440 2025-05-01
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
Tongji Hospital
Phase 2 Recruiting
NCT04840186 2024-11-12
EXCALIBUR3
Oslo University Hospital
Phase 2 Suspended
NCT05471674 2023-02-01
Neoadjuvant Anti-PD1 in HCC
The University of Hong Kong
Phase 2 Completed
NCT00153998 2009-02-27
Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)
Technische Universität Dresden
Phase 2 Completed